000 01303 a2200361 4500
005 20250515095811.0
264 0 _c20080104
008 200801s 0 0 eng d
022 _a1423-0240
024 7 _a10.1159/000109956
_2doi
040 _aNLM
_beng
_cNLM
100 1 _aGleissner, Beate
245 0 0 _aGemtuzumab ozogamicin (mylotarg) for the treatment of acute myeloid leukemia--ongoing trials.
_h[electronic resource]
260 _bOnkologie
_cDec 2007
300 _a657-62 p.
_bdigital
500 _aPublication Type: Journal Article; Review
650 0 4 _aAminoglycosides
_xadministration & dosage
650 0 4 _aAntibodies, Monoclonal
_xadministration & dosage
650 0 4 _aAntibodies, Monoclonal, Humanized
650 0 4 _aAntineoplastic Agents
_xadministration & dosage
650 0 4 _aClinical Trials as Topic
_xtrends
650 0 4 _aGemtuzumab
650 0 4 _aGermany
650 0 4 _aHumans
650 0 4 _aLeukemia, Myeloid, Acute
_xdrug therapy
650 0 4 _aPractice Patterns, Physicians'
_xtrends
650 0 4 _aTreatment Outcome
700 1 _aSchlenk, Richard
700 1 _aBornhäuser, Martin
700 1 _aBerdel, Wolfgang E
773 0 _tOnkologie
_gvol. 30
_gno. 12
_gp. 657-62
856 4 0 _uhttps://doi.org/10.1159/000109956
_zAvailable from publisher's website
999 _c17577893
_d17577893